Intellectual Property India Publishes Patent Application for 'Human Complement Component 2 Binding Molecules' Filed by The Cleveland Clinic Foundation

MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202517096224 A) filed by The Cleveland Clinic Foundation, Cleveland, U.S.A., on Oct. 7, for 'human complement component 2 binding molecules.'

Inventor(s) include Lin, Feng.

The application for the patent was published on Nov. 14, under issue no. 46/2025.

According to the abstract released by the Intellectual Property India: "Provided herein are human complement component 2 (C2) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human C2 binding molecules (e.g., nanobodies) having a first, and optionally a second, single monomeric variable antibody domain (SMVAD) that comprises certain CDRs, and methods for using such molecules to treat complement-related diseases (e.g., dysregulated complement activation diseases). In certain embodiments, the SMVAD comprises camelid, human, or humanized framework regions."

The patent application was internationally filed on Mar. 06, 2024, under International application No.PCT/US2024/018604.

Disclaimer: Curated by HT Syndication.